

LSP LIFE SCIENCES FUND N.V.

Suspension of repurchases and sale of Shares

AMSTERDAM – 17:00, 25 April 2024 / LSP Life Sciences Fund N.V. (the “**Company**”) announces that as of today the total number of issued and outstanding shares in the capital of the Company (the “**Shares**”) is 100,000. In accordance with Dutch law and the articles of association of the Company (the “**Articles of Association**”), the Company's issued and outstanding share capital must always be at least ten percent (10%) of the Company's authorised share capital. As the Company's authorised share capital comprises 1,000,000 Shares, the Company will not be allowed to repurchase Shares to the extent this would cause the number of issued and outstanding Shares to become less than 100,000. Consequently, and in accordance with the prospectus with respect to the Company dated 26 June 2015 (the “**Prospectus**”), the Company is legally obliged to suspend the repurchase of Shares with immediate effect. Furthermore, in view of the proposed dissolution and liquidation of the Company, the Company has decided to suspend the sale of Shares with immediate effect.

On 19 April 2024 the Company convened its annual general meeting to be held on 31 May 2024 at 10:00 CEST (the “**AGM**”). The convening notice and all other documents relevant for the AGM (the “**AGM Documents**”) can be downloaded from the Company's website: <http://www.lspvc.com/funds/public.html>. In order to enable the Company to resume the repurchase of Shares, a resolution shall be put to vote at the AGM to amend the Articles of Association by decreasing the authorised share capital of the Company. Subject to the adoption of the resolution to amend the Articles of Association and subsequent implementation of such amendment, the Company will resume the repurchase of the Shares as soon as possible after the AGM to temporarily execute any further repurchases prior to the delisting of the Shares as explained in the AGM Documents.

LSP Life Sciences Fund N.V.

Bas Vaessen (General Counsel EQT Life Sciences)

+31 (0) 20 664 55 00

Bas.Vaessen@eqtpartners.com

Certain statements in this press release are “forward-looking statements” including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as “strategy,” “expects,” “plans,” “anticipates,” “believes,” “will,” “continues,” “estimates,” “intends,” “projects,” “goals,” “targets” and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the LSP Life Sciences Fund N.V. manager only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of the LSP Life Sciences Fund N.V. manager. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting the LSP Life Sciences Fund N.V.'s business. The LSP Life Sciences Fund N.V. manager expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.